Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) EBITDA: 2019-2025

Historic EBITDA for Benitec Biopharma (BNTC) over the last 5 years, with Jun 2025 value amounting to -$8.9 million.

  • Benitec Biopharma's EBITDA fell 86.90% to -$8.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$37.9 million, marking a year-over-year decrease of 73.58%. This contributed to the annual value of -$37.9 million for FY2025, which is 73.58% down from last year.
  • Latest data reveals that Benitec Biopharma reported EBITDA of -$8.9 million as of Q2 2025, which was up 38.55% from -$14.5 million recorded in Q1 2025.
  • In the past 5 years, Benitec Biopharma's EBITDA registered a high of -$3.5 million during Q1 2022, and its lowest value of -$14.5 million during Q1 2025.
  • For the 3-year period, Benitec Biopharma's EBITDA averaged around -$6.9 million, with its median value being -$5.5 million (2023).
  • Per our database at Business Quant, Benitec Biopharma's EBITDA grew by 12.60% in 2024 and then tumbled by 249.09% in 2025.
  • Quarterly analysis of 5 years shows Benitec Biopharma's EBITDA stood at -$4.9 million in 2021, then decreased by 14.21% to -$5.6 million in 2022, then dropped by 25.11% to -$7.0 million in 2023, then crashed by 32.67% to -$9.2 million in 2024, then tumbled by 86.90% to -$8.9 million in 2025.
  • Its EBITDA was -$8.9 million in Q2 2025, compared to -$14.5 million in Q1 2025 and -$9.2 million in Q4 2024.